Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study

Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study

Abstract Background Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) primarily relies on FOLFIRINOX (LV5FU- irinotecan – Oxaliplatine) and Gemcitabine – Nab-Paclitaxel in the first-line setting. However, second-lines remain less well-defined and there is limited data regarding third-line...

Full description

Bibliographic Details
Main Authors: A. Gueiderikh, A. Tarabay, M. Abdelouahab, C. Smolenschi, M. L. Tanguy, M. Valery, D. Malka, T. Pudlarz, A. Fuerea, V. Boige, A. Hollebecque, M. Ducreux, A. Boilève
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Cancer
Subjects:
Pancreatic adenocarcinoma
mPDAC
Erlotinib
Gemcitabine
FOLFIRINOX
Online Access:https://doi.org/10.1186/s12885-024-12016-z

Internet

https://doi.org/10.1186/s12885-024-12016-z

Similar Items